Editas medicine stock price.

Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stockNov 20, 2022 · Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street. View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksEDIT Stock 12 Months Forecast. $12.60. (43.51% Upside) Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $12.60 with a high forecast of $19.00 and a low forecast of $7.00. The average price target represents a 43.51% change from the last price of $8.78.

Price of Stock Editas Medicine (EDIT) Today.Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...

Nonetheless, the filing did say that Editas already raised $163.3 million from selling preferred stock to private investors like Bill Gates and Google Ventures, along with other backers like Sun ...Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksResearch Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and ...

Price of Stock Editas Medicine (EDIT) Today.

Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...

Nov 29, 2023 · The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $3.19 above the current market price. The public float for EDIT is 81.05M and currently, short sellers hold a 19.58% of that float. On November 29, 2023, EDIT’s average trading volume was 1.64M shares. EDIT) stock’s latest price update The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.Apr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.

May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …

The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Editas Medicine, Intellia Therapeutics, and Vertex …

According to About.com, how long medicine takes to absorb into the stomach depends on the type of medication, whether it is taken with food or on an empty stomach, and the ability of the medication to pass into the bloodstream.Oct 15, 2020 · The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD. They need the money for the next leg of the journey, and their stock price is as good as it'll likely get until more data comes out. Take Editas Medicine (EDIT 2.28%) as an example. On June 9, it ...In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.The current Editas Medicine [ EDIT] share price is $9.78. The Score for EDIT is 55, which is 10% above its historic median score of 50, and infers lower risk than normal. EDIT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an ...According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ...Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET.

EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. Apr 6, 2023 · Editas Medicine (EDIT 0.86%) and Bluebird Bio (BLUE 2.64%) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. Dec 1, 2023 · See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, ... Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksWith Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 525,000 shares issued upon exercise in full by the underwriters of their option to purchase additional shares.Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ...Why Editas Medicine Stock Charged Higher in January. By George Budwell – Feb 2, 2023 at 11:33AM Key Points. ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET.Instagram:https://instagram. downtown big skymonthly dividend paying mutual fundsskiing santasvans shoes stock Sep 29, 2023 · Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ... karyopharm therapeutics incbest motorcycle insurance in california Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ...Nov 30, 2023 · A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. best spreadsheet for budget 11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.EDIT - Editas Medicine Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)